A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy

Tomohiro Nishi, Yasuo Hamamoto, Junko Uemoto, Kei Onodera, Etsuko Warita, Yasuhiro Yamanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)


Trastuzumab is the first molecular-target medicine for gastric cancer in acknowledgment of the effectiveness and safety in a randomized controlled trial for the HER2-positive gastric cancer. The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma. We report a case of HER2-positive scirrhous gastric carcinoma we treated, for whom a complete response was obtained by trastuzumab combination therapy. He was a 62-year-old man. In April, 2006, he was diagnosed with metastatic scirrhous gastric carcinoma (mainly poorly-differentiated adenocarcinoma). We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. We confirmed the disappearance of the lesion at the 10 th cycle and judged it to be a complete response. The HER2 of advanced gastric cancer must be screened immediately without asking patients for their background or their clinical and pathologic features.

Original languageEnglish
Pages (from-to)2553-2555
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number13
Publication statusPublished - 2012 Dec



  • Diffuse type
  • Gastric carcinoma
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this